Fintel reports that on May 27, 2026, Jefferies upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from Hold to Buy.
Analyst Price Forecast Suggests 35.70% Upside
As of May 14, 2026, the average one-year price target for PTC Therapeutics is $91.80/share. The forecasts range from a low of $65.65 to a high of $130.20. The average price target represents an increase of 35.70% from its latest reported closing price of $67.65 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for PTC Therapeutics is 1,143MM, an increase of 38.19%. The projected annual non-GAAP EPS is -4.99.
What is the Fund Sentiment?
There are 361 funds or institutions reporting positions in PTC Therapeutics. This is an decrease of 221 owner(s) or 37.97% in the last quarter. Average portfolio weight of all funds dedicated to PTCT is 0.14%, an increase of 20.05%. Total shares owned by institutions increased in the last three months by 3.81% to 103,952K shares. 
The put/call ratio of PTCT is 0.23, indicating a bullish outlook.
What are Other Shareholders Doing?
Rtw Investments holds 7,746K shares representing 9.34% ownership of the company. No change in the last quarter.
Janus Henderson Group holds 7,193K shares representing 8.67% ownership of the company. In its prior filing, the firm reported owning 4,851K shares , representing an increase of 32.56%. The firm decreased its portfolio allocation in PTCT by 49.96% over the last quarter.
Vanguard Portfolio Management holds 4,805K shares representing 5.79% ownership of the company.
Wellington Management Group Llp holds 3,943K shares representing 4.75% ownership of the company. In its prior filing, the firm reported owning 3,867K shares , representing an increase of 1.91%. The firm decreased its portfolio allocation in PTCT by 86.18% over the last quarter.
Vanguard Capital Management holds 3,676K shares representing 4.43% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
